Detalles de la búsqueda
1.
Renal prognoses by different target hemoglobin levels achieved by epoetin beta pegol dosing to chronic kidney disease patients with hyporesponsive anemia to erythropoiesis-stimulating agent: a multicenter open-label randomized controlled study.
Clin Exp Nephrol
; 25(5): 456-466, 2021 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-33411115
2.
Incidence of osteonecrosis of the jaw in Japanese osteoporosis patients taking minodronic acid.
J Bone Miner Metab
; 37(5): 886-892, 2019 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-30719580
3.
Study design of multi-center, open-label randomized controlled, head-to-head trial comparing minodronic acid and raloxifene: Japanese Osteoporosis Intervention Trial (JOINT)-04.
J Bone Miner Metab
; 37(3): 491-495, 2019 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-30019249
4.
Effect of achieved hemoglobin level on renal outcome in non-dialysis chronic kidney disease (CKD) patients receiving epoetin beta pegol: MIRcerA CLinical Evidence on Renal Survival in CKD patients with renal anemia (MIRACLE-CKD Study).
Clin Exp Nephrol
; 23(3): 349-361, 2019 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-30291472
5.
Association between responsiveness to methoxy polyethylene glycol-epoetin beta and renal survival in patients with non-dialysis-dependent chronic kidney disease: A pooled analysis of individual patient-level data from clinical trials.
Nephrology (Carlton)
; 22(10): 769-775, 2017 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-27312361
6.
Influence of symptomatic periodontal disease on changes in skeletal bone density during medication therapy for osteoporosis in postmenopausal women: the Japanese Osteoporosis Intervention Trial (JOINT)-04 and JOINT-05.
Arch Osteoporos
; 17(1): 7, 2021 12 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-34958402
Resultados
1 -
6
de 6
1
Próxima >
>>